Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
August 10, 2021 1:34 PM EDTEarlier today, Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced positive interim results from its ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.
Results from the MAD portion of the trial demonstrated proof of biology as evidenced by a dose proportional induction in HBG mRNA and accompanying increases in HbF-containing reticulocytes... More
Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%
August 10, 2021 11:27 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) Halted on LUDP, Up 114%
